A new class of drugs, Lu-PSMA-617, track down i prostate cancers resistant achieving good success and extending the life of patients.
This was declared by an international team of researchers including Professor Johann de Bono, Professor of Experimental Cancer Medicine at the Institute of Cancer Research, London, and Medical Oncologist Advisor at the Royal Marsden NHS Foundation Trust, and Professor Ken Herrmann, Director of the Nuclear Medicine Clinic at the University Hospital from Essen, Germany.
Read Also
- Vaccination obligation, Galli: “If Draghi manages to introduce it, it will rise in my estimation” Sep 2, 2021
- Cry of Independence in Tlaxcala 2021: How it will be Sep 4, 2021
- Called vitamin, anti-aging skin Jul 12, 2020
- Heatwaves and Covid-19: Health authorities estimate the excess number of deaths in France this summer at 10,420 Nov 22, 2022
- Rennes: The biggest fest-noz in the world returns after two years of absence Nov 19, 2022
- Delta variant, heterologous vaccination responds better than homologous: the study Aug 20, 2021
- Stepanov told how fine the Ukrainians for no mask Jul 2, 2020